According to a recently published study, there is no enough evidence supporting the idea that second generation antipsychotics (SGAs), which were developed to reduce the extrapyramidal symptoms associated to first generation antipsychotics (FGAs), offer any advantage over FGAs for the treatment of schizophrenia. Continue reading
According to recent news, Eli Lilly´s drug for the treatment of schizophrenia, Pomaglutemad Methionil, has not covered the objective of the first of the two programmed Phase III clinical studies.
The company expected this drug not to show the secondary effects seen for other schizophrenia drugs, such as gain of weight and irregularities in reproductive hormones.
A review published in June this year in Nature Reviews in Drug Discovery, describes the difficulties in getting successful clinical trials with psychiatric drugs. It states that the main concern is the gap between the molecular/cellular mechanism of a given target and its effects in the neuronal circuits and behavioral/cognitive processes.